CJ CHEILJEDANG CORP. - Company Intelligence Brief

1. Business Overview

CJ CheilJedang Corp. is South Korea's largest food and bio-ingredients conglomerate, operating across multiple segments including processed foods, bio (amino acids, nucleotides, and food ingredients), and feed & livestock. The company is part of the larger CJ Group conglomerate and maintains significant global operations, particularly in the food science and biotechnology sectors.

[TRANSLATION NOTE: Specific segment performance details and business descriptions would require Korean original filings for precise translation verification.]

2. Financial Trend

CJ CheilJedang's financial performance shows a mixed trajectory. Revenue increased modestly from KRW 29,024 billion (FY2023) to KRW 29,359 billion (FY2024), representing only 1.2% growth. This follows a decline from KRW 30,080 billion in FY2022, indicating revenue has remained essentially flat over the three-year period.

Operating income improved from KRW 1,292 billion (FY2023) to KRW 1,553 billion (FY2024), reflecting a 5.3% operating margin in 2024 versus 4.5% in 2023 – a positive margin expansion. However, net income deteriorated sharply from KRW 559 billion (FY2023) to KRW 362 billion (FY2024), a 35% decline, suggesting significant non-operating expenses or financial costs.

Total assets stood at KRW 30,150 billion as of end-2024, with total liabilities of KRW 17,907 billion, yielding a debt-to-equity ratio of approximately 1.46x. Total equity increased to KRW 12,243 billion, showing a slightly improving balance sheet structure. The company maintained retained earnings of KRW 5,747 billion.

3. Ownership Structure

[TRANSLATION NOTE: Specific ownership data including controlling shareholder identity and foreign ownership percentage is not included in the provided financial statement data. This information would typically be found in separate DART filings such as major shareholder reports (최대주주 현황) which were not provided.]

Based on market knowledge, CJ CheilJedang is controlled by the Lee family through CJ Corporation as part of the broader CJ Group structure, but specific percentages cannot be confirmed from the provided data.

4. Key Risks

Profitability Pressure: Despite improving operating margins, the 35% collapse in net income while operating income rose suggests structural issues with financial costs, foreign exchange exposure, or associate company losses that are eroding bottom-line performance. The widening gap between operating profit (up 20% vs. FY2023) and net profit (down 35%) is concerning.

Revenue Stagnation: Three-year revenue trajectory shows the company is struggling to achieve top-line growth, with 2024 revenue still below 2022 levels. This indicates market share challenges or pricing pressures in core businesses despite operating in defensive food/bio sectors.

5. Investment Consideration

CJ CheilJedang offers exposure to Korea's food and bio-ingredients sector with improving operational efficiency, but faces significant headwinds from revenue stagnation and deteriorating net profitability that require closer examination of segment performance and non-operating items.

Analysis based on FY2024 audited consolidated financial statements filed March 2025.